SILO PHARMA, INC.: 10-Q filed 2022-11-10

Name: SILO PHARMA, INC.: 10-Q filed 2022-11-10
Creator: SILO PHARMA, INC.

What SILO PHARMA, INC. reported in its quarterly report filed 2022-11-10 (fiscal Q3 2022): 35 published measures, 105 facts as tagged in accession 0001213900-22-071252.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-10
Fiscal period: fiscal Q3 2022
Accession: 0001213900-22-071252 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SILO PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	13,049,420	USD
At 2021-12-31	10,490,189	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	1,196,001	USD
At 2021-12-31	1,427,923	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	11,853,419	USD
At 2022-06-30	7,874,037	USD
At 2022-03-31	8,503,203	USD
At 2021-12-31	9,062,266	USD
At 2021-09-30	10,150,952	USD
At 2021-06-30	3,765,833	USD
At 2021-03-31	4,227,823	USD
At 2020-12-31	1,280,695	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-09-30	12,253,023	USD
At 2021-12-31	9,837,001	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-983,246	USD	92
2022-01-01 to 2022-09-30	-2,245,720	USD	273
2022-04-01 to 2022-06-30	-658,402	USD	91
2022-01-01 to 2022-03-31	-604,072	USD	90
2021-07-01 to 2021-09-30	6,385,119	USD	92
2021-01-01 to 2021-09-30	4,992,427	USD	273
2021-04-01 to 2021-06-30	-461,990	USD	91
2021-01-01 to 2021-03-31	-930,702	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-2,611,633	USD	273
2021-01-01 to 2021-09-30	-1,504,145	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	4,940,948	USD	273
2021-01-01 to 2021-09-30	3,794,102	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	86,707	USD	273
2021-01-01 to 2021-09-30	6,843,070	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-5,508,297	USD
At 2021-12-31	-3,262,577	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	2,000,700	shares	92
2022-01-01 to 2022-09-30	1,987,170	shares	273
2021-07-01 to 2021-09-30	1,972,739	shares	92
2021-01-01 to 2021-09-30	1,871,898	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	2,000,700	shares	92
2022-01-01 to 2022-09-30	1,987,170	shares	273
2021-07-01 to 2021-09-30	1,993,869	shares	92
2021-01-01 to 2021-09-30	1,893,028	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.49	USD/shares	92
2022-01-01 to 2022-09-30	-1.13	USD/shares	273
2021-07-01 to 2021-09-30	3.2	USD/shares	92
2021-01-01 to 2021-09-30	1.8	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.49	USD/shares	92
2022-01-01 to 2022-09-30	-1.13	USD/shares	273
2021-07-01 to 2021-09-30	3.16	USD/shares	92
2021-01-01 to 2021-09-30	1.78	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2021-07-01 to 2021-09-30	19,133	USD	92
2021-01-01 to 2021-09-30	19,133	USD	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	96,529	USD	92
2022-01-01 to 2022-09-30	323,922	USD	273
2021-07-01 to 2021-09-30	54,943	USD	92
2021-01-01 to 2021-09-30	222,177	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-949,154	USD	92
2022-01-01 to 2022-09-30	-1,970,698	USD	273
2021-07-01 to 2021-09-30	-463,942	USD	92
2021-01-01 to 2021-09-30	-1,801,927	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	12,912,335	USD
At 2021-12-31	10,402,320	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	312,194	USD
At 2021-12-31	490,039	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	965,720	USD	92
2022-01-01 to 2022-09-30	2,020,396	USD	273
2021-07-01 to 2021-09-30	480,508	USD	92
2021-01-01 to 2021-09-30	1,851,621	USD	273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2021-09-30	58,447	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	16,566	USD	92
2022-01-01 to 2022-09-30	49,698	USD	273
2021-07-01 to 2021-09-30	16,566	USD	92
2021-01-01 to 2021-09-30	49,694	USD	273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	1,459	USD	92
2022-01-01 to 2022-09-30	4,378	USD	273
2021-07-01 to 2021-09-30	1,459	USD	92
2021-01-01 to 2021-09-30	3,544	USD	273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	60,341	USD	92
2022-01-01 to 2022-09-30	123,084	USD	273
2021-07-01 to 2021-09-30	24,618	USD	92
2021-01-01 to 2021-09-30	141,353	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	375,795	USD	92
2022-01-01 to 2022-09-30	651,750	USD	273
2021-07-01 to 2021-09-30	70,514	USD	92
2021-01-01 to 2021-09-30	217,962	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	3,138,797	shares
At 2021-12-31	1,972,739	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-09-30	12,253,023	USD
At 2021-12-31	9,837,001	USD
At 2021-09-30	10,261,416	USD
At 2020-12-31	1,128,389	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-09-30	17,361,402	USD
At 2021-12-31	12,324,646	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2022-09-30	64,800	USD
At 2021-12-31	61,210	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2022-09-30	581,373	USD
At 2021-12-31	145,324	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-983,246	USD	92
2022-01-01 to 2022-09-30	-2,244,557	USD	273
2021-07-01 to 2021-09-30	6,491,571	USD	92
2021-01-01 to 2021-09-30	5,239,029	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-283	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-34,092	USD	92
2022-01-01 to 2022-09-30	-273,859	USD	273
2021-07-01 to 2021-09-30	6,955,513	USD	92
2021-01-01 to 2021-09-30	7,040,956	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	2,079	USD	273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	25,159	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	4,940,948	USD	273

Inspect the source

Entity: SILO PHARMA, INC. / CIK 0001514183
Captured: 2026-09-20T09:13:20.337Z
SEC response SHA-256: b55b01ff5b31c52a933a54029f5fe837eae02333bd43de16acad37f51e3b67db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001514183.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))